PCSK9 inhibitors in real clinical practice: whom, when and how?

• Marina V. Zhuravleva
• Kokushkin K.A.
• Prokofiev A.V.
• Svetlana Yu. Serebrova
• Kukushkin G.V.
• Lazareva Natalia B.

Abstract

The article considers the place of PCSK9 inhibitors in the prevention of cardiovascular complications in patients with high cardiovascular risk in accordance with international and Russian guidelines. The algorithm for consideration of PCSK 9 inhibitor treatment in patients with atherosclerotic cardiovascular diseases is discussed. Particular attention is paid to the role of PCSK9 inhibitors in the treatment of dyslipidemia and improving outcomes in patients with recent acute coronary syndrome and in patients with diabetes mellitus and concomitant atherosclerotic cardiovascular diseases. The issues of provision of patients with PCSK9 inhibitors with reference to Russian conditions are described in details.

Keywords: PCSK9 inhibitors, cardiovascular diseases, atherosclerosis, dyslipidemia, acute coronary syndrome, diabetes mellitus

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)